Technologies

ImmBio develops vaccines that protect against pathogens by mimicking the natural immune response to infection.

ImmBioVax™

Based on insights into the role of heat shock proteins in the immune response to pathogens, ImmBio developed and patented a new vaccine technology ImmBioVax™. The resultant products:

  • Confer broad protection to protect diverse human populations
  • Do not require the addition of adjuvants
  • Emulate a normal infection and are predicted to posses a good safety profile
  • Possess low production costs

 

ImmunoBodies™

ImmunoBodies are antibody-antigen fusion proteins. ImmBio has developed this technology and established a cross-license agreement for ImmunoBodies with Scancell Ltd. The resultant products:

  • Can be developed rapidly by a clear regulatory path
  • Possess rapid manufacturing cycle time and low production costs
  • Do not require adjuvants 

More information is provided in the publications link on this page.

 

Intellectual Property: Patent portfolio comprises twelve families addressing composition, manufacture and use of multi-protein complex based vaccines. Trademarks include company and vaccine product names.  Know-how includes  product constructs, process design and assays.